Thermo Fisher Scientific and Datavant are partnering, facilitating connection of real-world data with clinical research for pharmaceutical and biotech companies. The strategic data collaboration between the two companies helps others in the industry generate stronger evidence at a faster clip.

As a data collaboration platform, Datavant already engages more than 350 real-world data partners and 80,000 U.S. hospitals and clinics. For these partners, Datavant enables privacy-preserving tokenization as well as linkage of patient-level data.

How Thermo Fisher, Datavant Combine

Connecting with Thermo Fisher’s PPD clinical research business, Datavant will endeavor to enable secure connection and analysis of real-world data. This spans real-world data enrichment of randomized clinical trials, plus solutions (CorEvitas Clinical Registries, Evidera) under the PPD umbrella.

That branch of Thermo Fisher, with Datavant’s help, will then be able to securely connect de-identified research datasets. Subsequently, it can retrieve consented electronic medical record data for bespoke real-world data generation.

Datavant’s encrypted token technology will be integrated within Thermo Fisher’s real-world data infrastructure. This will allow biopharmaceutical and biotech customers to access enhanced linked patient data and advanced analytics. In turn, that access should ideally result in the design of more connected studies, improved recruitment, and accelerated evidence generation.

In Context With Other Moves

Thermo Fisher has recently invested broadly in digital innovation, including a strategic collaboration with OpenAI. Karen Kaucic, MD, president, patient and advisory services, and chief medical officer, clinical research, Thermo Fisher Scientific, reflected on this.

“Data interoperability is critical to the next generation of evidence generation,” Kaucic said. “By enabling privacy-protected data connectivity at scale, [Datavant’s] collaboration allows us to deliver a more seamless and efficient research experience.”

Arnaub Chatterjee, general manager and president of Life Sciences at Datavant, also weighed in.

“Reducing friction across the research lifecycle—from clinical trials through real-world evidence—is key,” Chatterjee said. “Our shared life sciences partners can generate insights faster and advance better outcomes for patients.”